We’ve said it before and we’ll say it again: someone you know struggles with mental health. And, if they don’t, they might suffer from something physical, such as arthritis, or migraines or back pain.

Genesight is critical to the growth of MYGN - at the very least the test is going to run into pricing headwinds via a new coverage policy form CMS (rate should decrease from ~$2,200 to under $800 ...

SALT LAKE CITY, July 12, 2022 (GLOBE NEWSWIRE) -- Major Depressive Disorder (MDD) remission rates were significantly improved when clinicians had access to GeneSight ® Psychotropic test results ...

SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced enhancements to the GeneSight® Psychotropic ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective ...